A second global pivotal trial will test iza-can in the same NSCLC setting where patri-dxd failed.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.